Publication | Closed Access
Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.
140
Citations
16
References
1996
Year
VNLB led to a 21% response rate in the population of heavily pretreated and platinum-resistant ovarian cancer patients. Further studies of VNLB alone or in combination with taxanes are warranted in patients with less pretreatment.
| Year | Citations | |
|---|---|---|
Page 1
Page 1